7
We investigated parameters of specific CD8 T cell response and in vitro susceptibility 8 to HIV-1 infection in 11 HIV controllers. We found high frequencies of HIV-specific 9 CD8+ T cells. Interestingly, these cells expressed the activation marker HLA-DR but 10 not CD38. This unique phenotype differentiates HIV-specific CD8 T cells from HIV 11 controllers and non-controller subjects and likely reflects a high potential to expand 12 upon exposure to antigen and a capacity to exert effector functions. Accordingly, 13
although their CD4+ T cells were fully susceptible to HIV-1 superinfection, CD8+ T 14 cells from HIV controllers effectively suppressed HIV-1 infection. Remarkably, this 15 potent anti-HIV activity was observed without prior stimulation of CD8+ T cells. It was 16 not mediated by secreted inhibitory factors, was due to the elimination of infected 17 CD4+ T cells and was only observed with autologous CD4+ T cells, indicating an HLA-18 restricted cytotoxic mechanism. This constitutive antiviral capacity of CD8+ T cells 19 could account for the control of viral replication in HIV controllers. 20 21 22
INTRODUCTION 1
We examined the activation status of CD8+ T cells by evaluating HLA-DR and CD38 1 expression. HIV-specific CD8+ T cells showed low expression of CD38 (15% ± 9%, 2 similar to that observed among the total CD8+ T cell population: 19% ± 5%) ( Fig. 2B) . 3
In contrast, HIV-specific CD8+ T cells expressed a high level of HLA-DR (52% ± 4 17%), higher than that observed among total CD8+ T cells (25%  16%, P = 0.001) 5 (Fig. 2B ). This may suggest an activation of HIV-specific CD8+ T cells, which is 6 unexpected in subjects with undetectable plasma RNA levels, and puzzling in the 7 absence of high CD38 expression ( Fig. 6A) . Actually, HIV-specific CD8+ T cells from 8 viremic subjects exhibited high expression of both CD38 and HLA-DR (51%  20% 9 and 46  21%, respectively), whereas those from HAART subjects had low expression 10 of these two markers (11%  8% and 26  20% for CD38 and HLA-DR, respectively), 11 (Figure 2C and 6A) . In addition to activation, expression of HLA-DR has been 12 associated with proliferation (14). HIV-specific CD8+ T cells from HIV controllers had 13 a high proliferation capacity (on average, 60%  31% of HIV-specific CD8+ T cells that 14 proliferated) that was positively correlated to the expression of HLA-DR (P Spearman = 15 0.03)(data not shown). This profile may rather reflect the capacity to proliferate than 16 ongoing proliferation in vivo, as Ki-67 expression was low on ex vivo HIV-specific 17 CD8+ T cells (data not shown). Consistent with a high proliferative potential, in 18 proliferation assays all CFSE low specific CD8+ T cells were HLA-DR+ ( Fig. 6B ). 19
Finally, we observed a mutually exclusive expression of HLA-DR and the CD57 marker 20 on HIV-specific CD8+ T cells ( Figure 6C and data not shown). 21
22

Ex vivo unstimulated HIC CD8+ T cells control HIV-1 infection 23
Seeking a direct link between the particular CD8+ T cell response in HIC and the 24 control of viremia, we next evaluated the capacity of circulating HIC CD8+ T cells to 25 Lacabaratz et al. Revised. 7 suppress, in the absence of exogenous stimulation, HIV-1 infection in autologous CD4+ 1
T cells. 2
Purified CD4+ T cells from HIC supported viral replication at levels similar to those 3 observed in healthy controls (2520 ± 997 and 2729 ± 1248 ng p24/ml at the peak of 4 viral replication in the 11 HIC and 12 healthy controls, respectively) ( Fig. 3A) . As 5 expected (15) , the levels of viral replication in CD4+ T cells from 10 untreated viremic 6
HIV-1-infected individuals were highly heterogeneous (2331 ± 2204 ng p24/ml) (Fig. 7 3A) . 8
When cocultures of CD4+ T cells and autologous unstimulated CD8+ T cells were 9
infected with HIV-1, viral replication was undetectable in 9 out of the 10 HIC tested 10 (4.0 ± 1.1 log p24 decrease, CD8:CD4 vs CD4, n=10) and strongly reduced in the 11 remaining subject, B2 (Fig. 3A ) who, interestingly, showed also the lowest HIV-12 specific CD8+ T cell response (see Fig. 1A : 130 SFC/10 6 PBMC, 1 peptide recognized) . 13 In contrast, unstimulated CD8+ T cells from healthy donors were devoid of antiviral 14 activity (0.1 ± 0.2 log p24 decrease, CD8:CD4 vs CD4, n=12) and unstimulated CD8+ 15 T cells from viremic individuals were never able to efficiently control HIV-1 16 superinfection in autologous CD4+ T cells (0.9 ± 0.6 log p24 decrease, CD8:CD4+ at 17 1:1 ratio vs CD4, n=9) ( Fig. 3A ). Furthermore, the antiviral activity of CD8+ T cells 18 from viremic individuals was rapidly lost when CD8+ T cells were diluted, whereas 19 HIC CD8+ T cells were still fully effective at a ratio of 0.1 CD8+ T cell to 1 CD4+ T 20 cell ( fig. 3B ). 21
This remarkable anti-HIV-1 activity of unstimulated HIC CD8+ T cells was observed 22 with a wide range of infectious doses (BaL HIV-1 m.o.i. = 10 -2.8 to 10 -0.8 ) (data not 23 shown) both with laboratory-adapted HIV strains and primary isolates, regardless of 24 clade and tropism (HIV-1 NL4.3 (X4); 132W (dual tropic), subtype E; DH12 (dual tropic) and BX08 (R5), subtype B), (data not shown). Experiments performed without 1 exogenous IL-2 (that was regularly present in the coculture medium) showed, as 2 expected, a reduced viral replication in infected CD4+ T cells, but the antiviral capacity 3 of HIC unstimulated CD8+ T cells did not depend on the presence of the cytokine (Fig.  4 7). In order to clarify the mechanism(s) responsible for the control of HIV-1 infection in the 9 cells from HIC, we assessed the role of soluble factors (16, 17) . In HIC, the control of 10 HIV-1 replication was totally lost when unstimulated CD8+ T cells were separated from 11 autologous CD4+ T cells by semi-permeable membranes (Fig. 4A ). By contrast, when 12 mitogen-activated CD8+ T cells were separated from autologous CD4+ T cells by semi-13 permeable membranes, a (modest) reduction in viral replication mediated by soluble 14 factors, was observed in HIC and also frequently in healthy donors ( Fig. 4A ). Therefore 15 HIC CD8+ T cells, although able to secrete inhibitory soluble factors upon in vitro 16 stimulation, do not exert their potent anti-HIV-1 activity ex vivo through this 17 mechanism. 18 19
CD8+ T cells from HIV controllers eliminate the HIV-1 infected CD4+ T cells 20
To evaluate whether the observed control of HIV-1 infection was achieved through the 21 physical elimination of infected CD4+ T cells by HIC CD8+ T cells, we removed CD8+ 22 T cells from superinfected autologous cocultures. The removal of the CD8+ T cells 23 would be expected to rescue HIV-1 replication in the re-purified CD4+ T cells only if 24 Sáez-Cirión, Lacabaratz et al. Revised.
9
HIV-1 control was caused by a CD8-mediated intracellular block, such as the post-1 integration inhibition induced by the antiviral factor CAF (18) . 2 Single-round infections with pseudotyped HIV-1 particles were used to avoid confusing 3 contribution of subsequent viral replication. A marked control of HIV-1 infection was 4 observed at 48h when HIC unstimulated CD8+ T cells were cocultured with autologous 5 CD4+ T cells (Fig. 4B, left) . The coculture was then split and CD8+ T cells were 6 depleted from one of the two resulting cocultures. Two days later a comparable strong 7 reduction of HIV-1 infection was observed in both cultures (figure 4B, center). 8
However, when the two cultures were re-challenged with the HIV-1 pseudotype, the 9 CD8-depleted culture was readily superinfected whereas control of infection was still 10 observed in the non depleted coculture (Fig. 4B, right) . These results are compatible 11 with a CD8+ T cell-mediated elimination of infected CD4+ T cells. Consistent with this, 12 the addition of HIC CD8+ T cells to autologous CD4+ T cells that had been infected for 13 2 days with GFP reporter HIV-1 particles, provoked a reduction in the number of 14 infected GFP-positive CD4+ T cells ( Fig. 4C ). 15
16
Anti-HIV-1 activity of HIC CD8+ T cells requires contact with autologous CD4+ T 17 cells 18
The precedent results strongly supported that control of HIV-1 infection was mediated 19 by a cytotoxic mechanism. To find out if the HIC CD8+ T cell antiviral activity was 20
MHC-restricted, we assessed the capacity of unstimulated HIC CD8+ T cells to control 21
HIV-1 infection in autologous and heterologous CD4+ T cells. The same HIC CD8+ T 22 cells that were able to control HIV-1 in vitro when cocultured with autologous CD4+ T 23 cells, were ineffective when cocultured with heterologous CD4+ T cells both from HIC 24 Sáez-Cirión, Lacabaratz et al. Revised. 10 and from healthy controls (Fig. 4D) . These results support an MHC-restricted 1 mechanism of suppression. 2 3 DISCUSSION 4
Here we provide the first evidence that HIV-specific CD8+ T cells from HIV controllers 5 are characterized by a unique CD38 low /HLA-DR high phenotype, which likely reflects a 6 capacity to proliferate upon antigenic stimulation and exert effector functions. 7 Importantly, we also report that circulating HIC CD8+ T cells are able to efficiently 8 control HIV-1 infection ex vivo, without further stimulation, suggesting that this 9 antiviral activity is functional in vivo. This CD8+ T cell-mediated control is independent 10 of the secretion of antiviral molecules, requires contact with their matching CD4+ T 11 cells, and is caused by the elimination of infected CD4+ T cells, likely due to HIV-12 specific CD8+ T cells. This previously undescribed spontaneous capacity of CD8+ T 13 cells to clear the virus through the killing of infected cells is particular to HIV 14 controllers. 15 16 In keeping with previous studies in a comparable group of patients (7, 8), we observed 17 that most HIC possessed high frequencies of IFN-secreting HIV-specific CD8+ T cells 18 that, overall, did not differ from those seen in chronically viremic patients and were 19 strikingly higher than those observed in HAART-treated non viremic patients (Fig. 1 20 and (7, 8, 19, 20) ). These HIV-specific CD8+ T cells had a broad repertoire, particularly 21 in HLA-B27 and/or HLA-B57-positive individuals. 22
23
The high proliferative potential observed in HIC has been previously proposed (8) 24 together with high functionality (9) as hallmarks of a high-quality HIV-specific CD8 T+ cell response in HIC. However, no phenotypical differences had been found so far that 1 might distinguish HIC from other patients and be associated with an effective immune 2 response. We evaluated the differentiation status of HIC HIV-specific CD8+ T cells as 3 the skewed maturation of these cells may partly explain the lack of effective control of 4 HIV replication in most HIV-infected patients (21) (22) (23) (24) (25) . We observed that HIV-specific 5 CD8+ T cells were indeed more differentiated in HIC than in HIV-viremic patients (21, 6 26 ). Nevertheless, variable profiles were observed within and among the HIC, and, 7 therefore, optimal differentiation of their specific CD8+ T cells does not appear as a 8 distinctive element to explain the effective control of infection. 9
10
The activation phenotype of HIV-specific CD8+ T cells in HIC had not been previously 11 defined. We and others have shown a positive correlation between the level of viral 12 replication and the activation status of HIV-specific CD8+ T cells (26-28). Accordingly, 13
and in contrast to viremic controls, CD38 expression by HIV-specific CD8+ T cells 14 from HIV controllers was very low in this study. Conversely, HLA-DR expression was 15 remarkably high, differently from HAART patients, and much higher than that observed 16 on the total CD8+ T cell population. An increased HLA-DR expression associated with 17 a low CD38 expression had been reported on the global CD8+ T cell population in 18 asymptomatic HIV-infected patients with stable CD4+ T cell counts (29) . In HIV 19 controllers we observed that the discordance between the expression of CD38 and HLA-20 DR was much more pronounced on HIV-specific CD8+ T cells what is puzzling in the 21 context of high and long-lasting viral control. The low expression of CD38 may reflect 22 the lack of general immune activation and the expression of HLA-DR may actually 23 characterize T cells with high proliferative potential. This hypothesis is supported by 24 several data: (i) although we found little evidence of in vivo cycling or proliferation, as very few HIV-specific CD8+ T cells expressed Ki67, HIV-specific CD8+ T cells from 1 HIV controllers had potent in vitro proliferative capacity upon exposure to antigen; (ii) 2 most HLA-DR pos HIV-specific CD8+ T cells did not express the senescence marker 3 CD57 which lack of expression has been clearly linked to proliferative capacity (30); 4 (iii) finally, we observed a correlation between HLA-DR expression and the percentage 5 of proliferating CFSE low cells among HIV-specific CD8+ T cells. 6 7 Although the control of HIV-1 replication in HIC has been associated with a strong, 8 multifunctional specific CD8 T cell response, the anti-HIV activity of HIC CD8+ T 9 cells had not been thoroughly addressed and a direct link between the immune response 10 and the control of viremia was lacking. First, we show that HIC CD4+ T cells are highly 11 susceptible to HIV-1 in vitro infection, discarding, therefore, that an intrinsic resistance 12 of CD4+ T cells to HIV-1 could contribute to HIC status. Second, we found that HIC 13 purified CD8+ T cells were able to efficiently control HIV-1 infection in vitro of 14 autologous CD4+ T cells, even if 10 times more diluted than the CD4+ T cells. Our 
13
Although CD8+ T cells in HIV patients have been reported to be able to suppress HIV 1 infection through the secretion of soluble factors (reviewed in (17)) or HLA-class I 2 restricted cytolysis (31-33), the relative weight of these mechanisms is controversial. 3
We demonstrate that the ability of HIC CD8+ T cells to control HIV-1 infection ex vivo 4 is not linked to the secretion of soluble factors and required contact with infected CD4+ 5 T cells. The contact of CD8+ T cells with CD4+ T cells did not induce the production of 6 a restriction factor in the latter but rather the elimination of the infected cells. This 7 antiviral activity was effective on autologous CD4+ T cells only. Altogether, our results 8 point to HLA-restricted cytotoxicity as the mechanism associated to the in vivo control 9 of infection achieved by HIV controllers. 10
11
In conclusion, we provide direct evidence that circulating CD8+ T cells from HIC are 12 spontaneously able to control HIV-1 infection, a striking difference with cells from 13 viremic subjects. Our study strongly suggests a pivotal role of HIV-specific CD8+ T 14 cells in viral control in these individuals. These cells have a unique phenotype which 15 may correspond to activated status in vivo but more likely reflects a propensity to 16 expand rapidly upon antigen exposure. This capacity is probably linked to an intact 17 ability to secrete IL-2 and other cytokines (9, 34) and may explain the maintenance of 18 high frequencies of HIV-specific CD8+ T cells in these subjects. The generation of this 19 optimal CD8+ T cell profile is a major research focus. Further studies should provide 20 new insights into the precise mechanisms of HIV control and may serve to a better 21 design of future vaccination or immune-based therapies. Already, both the expression of 22
HLA-DR and CD38 on HIV-specific CD8+ T cells and their capacity to suppress ex 23 vivo HIV-1 might be used as surrogate markers to evaluate the efficiency of induced 24 CTL responses in vaccine trials.
1
MATERIALS AND METHODS 2
Study subjects 3
Eleven patients infected by HIV-1 for > 10 years who had never received antiretroviral 4 treatment and in whom more than 90% of plasma HIV RNA load tests gave values <400 5 copies/ml (HIV controllers) were studied here: 9 have been described elsewhere (5) (Miltenyi Biotech, France). CD4+ cells were stimulated for 3 days with 21 phytohaemagglutinin (PHA) at 1 µg/ml in the presence of interleukin-2 (IL-2) (Chiron, 22 France) at 100 IU/ml. The culture medium was RPMI 1640 containing 10% FCS and 23 penicillin/streptomycin (100 U/ml). CD8+ T cells were kept in culture without mitogens 24 or cytokines.
1
Viruses and productive infection in vitro 2
Results shown were obtained performing infections in vitro with HIV-1 BaL (R5) at 3 m.o.i. 10 -2.8 . CD4+ T cells (10 5 ) were infected in triplicate in 96-well plates with a 4 spinoculation protocol (35). For coculture, 10 5 CD4+ T cells were mixed with 10 5 5 CD8+ T cells (CD8/CD4 ratio 1:1) or with 10 4 CD8+ T cells (CD8/CD4 ratio 0.1:1) at 6 the moment of infection. After infection the cells were washed and cultured for 14 days. 7
HIV-1 replication was monitored every 3-4 days in supernatants by p24 ELISA 8 (Beckman-Coulter, France). Unless otherwise indicated, infectivity assays were carried 9 out in the presence of 100 IU/ml IL2. 10 11
Single-round infections 12
BaL and VSV-G pseudotyped HIV-1 particles were produced by co-transfecting 13 (SuperFect, Qiagen) 293T cells with the proviral pNL-Luc-E-R+ (36) or pNL-GFP-E-14 R+ (37) and BaL-Env or VSV-G expression vectors. CD4+ T cells (10 5 ) were infected 15 in triplicate with HIV-1 pseudotypes, as above. Luciferase activity was assessed in cell 16 lysates (Luciferase Reporter 1000 Assay System, Promega France) in a Veritas 17 microplate luminometer (Turner BioSystems, CA, USA) as described (38). 18
19
Peptides 20
We used a set of 124 peptides corresponding to known optimal CTL epitopes (NIH HIV 21 Molecular Immunology Database: http://www.hiv.lanl.gov/content/immunology/index.html. 22
The peptides were synthesized by Neosystem (Strasbourg, France). They were used at a 23 final concentration of 2 µg/mL. 24
Elispot assay 1
Interferon (IFN)- secretion by HIV-specific CD8 + T cells was quantified with an 2 ELISPOT assay using appropriate stimuli (HLA-defined optimal peptides derived from 3 the HIV-1 Env, Gag, Pol and Nef proteins or controls) (20) . IFN- spot-forming cells 4 (SFCs) were counted with a KS-ELISPOT system (Carl Zeiss Vision) and expressed as 5 SFCs/10 6 PBMC after subtracting the background. Wells were considered positive if 6 they contained at least 50 SFCs/10 6 PBMC and exhibited at least two times the 7 background level. Immunomics. PBMC were incubated with tetramers (1 µg/mL) for 30 min and then 23 with relevant antibodies for 15 min. Cells were washed in Cell Wash (BD Biosciences) 24 plus 1% BSA, incubated for 10 min with FACS lysing solution (BD Biosciences) and washed. For intracellular staining, cells were incubated for 10 min with FACS 1 permeabilizing solution (BD Biosciences) before adding antibodies for 30 min. Cells 2 were fixed in 1% paraformaldehyde for flow cytometry with a Beckman Coulter Epics 3 XL cytometer and RXP software (Beckman Coulter). 4 5
Proliferation assay 6
The proliferative capacity of HIV-specific CD8+ T cells was evaluated by flow 7 cytometry. PBMC were stained with 0.35 µM carboxyfluorescein diacetate 8 succinimidyl ester (CFSE, Molecular Probes, The Netherlands) for 10 min at 37°C, and 9 then stimulated for 5 days with 2 µg/mL peptide or medium alone. After labelling with 10 tetramer, anti-CD8, anti-CD3 and/or anti-HLA-DR antibodies, PBMC were fixed in 1% 11 added to Transwell (orange patterned bars). The ratio of CD8+ to CD4+ T cells was 1:1. 24
One representative experiment with HIV controller A1 and one uninfected control is
